Saturday, December 25, 2021 10:55:21 AM
Cumberland Emerging Technologies
Cumberland Emerging Technologies (CET) provides access to a long term pipeline of innovative, biopharmaceutical product candidates. CET was established as a joint initiative between Cumberland Pharmaceuticals Inc., Vanderbilt University and the state of Tennessee to identify innovative product candidates and advance them from the laboratory to the marketplace. CET has formal collaboration agreements with leading academic research centers located in the mid-south region of the United States. Through these research centers CET evaluates a range of new emerging technologies and then teams with scientist to develop promising candidates.
In addition to these development partnerships, CET manages a Life Sciences Center to support its activities and to help support the growth of the biomedical industry within Tennessee and the region.
https://www.cumberlandpharma.com/cumberland-emerging-technologies
Recent CPIX News
- CUMBERLAND PHARMACEUTICALS ANNOUNCES LAUNCH OF VIBATIV® IN CHINA • PR Newswire (US) • 05/28/2026 01:05:00 PM
- Form DEFM14A - Definitive proxy statement relating to merger or acquisition • Edgar (US Regulatory) • 05/26/2026 10:00:54 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2026 09:02:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/05/2026 09:07:03 PM
- CUMBERLAND PHARMACEUTICALS REPORTS Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE • PR Newswire (US) • 05/05/2026 09:00:00 PM
- CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE • PR Newswire (US) • 04/28/2026 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/24/2026 09:08:24 PM
- Cumberland Pharmaceuticals jumps on $100M Apotex transaction • IH Market News • 04/23/2026 02:52:23 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/23/2026 01:02:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/23/2026 01:01:32 PM
- Cumberland Pharmaceuticals Announces Strategic Transaction to Integrate Commercial Business with Apotex • PR Newswire (US) • 04/23/2026 01:00:00 PM
- RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026 • PR Newswire (US) • 04/22/2026 12:00:00 PM
- CUMBERLAND PHARMACEUTICALS ANNOUNCES EXPANDED INDICATION FOR CALDOLOR® (IBUPROFEN) INJECTION AND LAUNCH OF NEW BRAND WEBSITE • PR Newswire (US) • 04/16/2026 01:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 09:24:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 09:23:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 09:22:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 09:21:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 09:21:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 09:20:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 09:20:05 PM
- Cumberland Pharmaceuticals Launches New Sancuso® Website Featuring Educational Resources for Chemotherapy-Induced Nausea and Vomiting • PR Newswire (US) • 03/17/2026 01:05:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/12/2026 09:00:17 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/09/2026 09:03:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/09/2026 09:01:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 10:10:28 PM
